Anne Wojcicki is poised to regain control of genetics testing company 23andMe, which she cofounded and led until earlier this year, after agreeing to put much of her personal fortune on the line. Why it matters: This is the same person that 23andMe customers originally trusted with their personal data, albeit under a much more opaque governance structure. Catch up quick: Regeneron Pharma in May won a bankruptcy auction for 23andMe's assets, bidding $265 million, beating out Wojcicki (who'd been trying to purchase the company since well before the Chapter 11 filing ). Behind the scenes: Wojcicki made the offer through TTAM Research Institute, a public-benefit corporation formed just last month. Look ahead: A court hearing to approve Wojcicki's bid is scheduled for tomorrow. The bottom line: Even if she clears all the legal hurdles, it remains unclear how Wojcicki plans to make 23andMe into a viable business (even if under a nonprofit umbrella). Go deeper: 23andMe bankruptcy underscores health privacy gaps